“The Massachusetts-based biotechnology company announced the favorable outcome following a meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The panel voted 10-3 that the results from a key clinical study of the company’s therapy, known as RP1,… Continue Reading…